NARRATIVE REVIEW2023
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.
Gravina AG, Pellegrino R, Durante T, et al. Cells. 2023;12(14):1889.
What they did. A team of gastroenterologists reviewed what is known about the melanocortin system (alpha-MSH, ACTH and related peptides, including KPV) and its link to gut inflammation in inflammatory bowel disease.
What they found. The authors say most of the evidence comes from mouse models of colitis. In those models, melanocortin-pathway molecules affected the balance of inflammatory signals in the gut. They present these molecules as possible future drug candidates, not as proven treatments. This is a narrative review, not a systematic one, and it does not establish any effect in people.
Why it matters for testing. The review covers several related melanocortin peptides and analogues, which shows how many look-alike molecules exist in this family. A KPV result should confirm the exact sequence and mass, not just a melanocortin-like peptide.
PRECLINICAL ANIMAL STUDY2008
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
Kannengiesser K, Maaser C, Heidemann J, et al. Inflammatory Bowel Diseases. 2008;14(3):324-331.
What they did. Researchers gave KPV to mice in two different chemically or immunologically induced colitis models. They also tested mice whose MC1R receptor (a melanocortin receptor) does not work.
What they found. Treated mice regained weight sooner and had less inflammation in colon tissue than untreated mice in both models. Treated mice that lacked a working MC1R receptor also survived, which suggests the effect does not depend entirely on that receptor. This was a mouse-only study, the PubMed abstract does not give group sizes, and the results cannot be applied to humans.
Why it matters for testing. Studies like this use a defined, characterised peptide. A retail vial labelled KPV is only comparable if mass and purity testing show that it holds the same free tripeptide and not an acetylated, amidated or rearranged variant.
PRECLINICAL CELL AND ANIMAL STUDY2008
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. Gastroenterology. 2008;134(1):166-178.
What they did. Using human intestinal and immune cell lines and two mouse colitis models, the researchers studied how KPV gets into cells and how it affects inflammatory signalling.
What they found. In cell culture, KPV dampened major inflammatory signalling pathways and lowered inflammatory cytokine release. The cells took it up through PepT1, a transporter that carries small di- and tripeptides. In both mouse models, colitis was less severe in KPV-treated animals. The work is limited to cell lines and mice, the PubMed abstract does not give animal numbers, and no human data were collected.
Why it matters for testing. PepT1 carries many different di- and tripeptides, and rearranged tripeptides such as Lys-Val-Pro have exactly the same mass as KPV. Identity testing therefore needs sequence confirmation (MS/MS fragments or a reference standard), not just a match on molecular weight.
Know what is in your vial
See every KPV lot we have tested, or send yours in.
Summaries are written by Vialidate Labs from the published articles, via PubMed. Read the original papers for full methods and results. Vialidate reports analytical results only; nothing on this page is medical advice or a recommendation to use any compound.